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Permanent intestinal failure, whether secondary to 
severe gastrointestinal tract dysfunction or short 
bowel syndrome, remains a challenging pediatric 
health problem that requires innovative therapeutic 
modalities. Steatorrhea and intractable diarrhea re-
sult in failure to thrive, hypovitaminosis, hypopro-
teinemia, electrolyte disturbance, and metabolic aci-
dosis if parenteral alimentation (TPN) is begun too 
late. A variety of medical and surgical treatments 
have been devised to address each of the underlying 
causes of childhood intestinal failure. Nonetheless, a 
significant percentage of children with intestinal fail-
ure remain permanently bound to parenteral nutri-
tion. While some of these children suffer minimal 
morbidity, others succumb to the life-threatening 
complications of TPN. Until recently they had no 
hope for survival, but within the past decade small 
intestinal transplantation has offered them an oppor-
tunity for prolonged life emancipated from the shack-
les of TPN. 
In this review, we shall discuss in detail microvillus 
inclusion disease. intestinal pseudoobstruction. and 
short bowel syndrome. which are the most common 
causes of pediatric intestinal failure coming to intes-
tinal transplantation. The factors facilitating intesti-
nal adaptation or predisposing to irreversible liver 
disease in children with short bowel syndrome will be 
described. We shall also enumerate the indications 
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for pediatric intestinal transplantation and outline the 
surgical techniques, postoperative management, and 
results of our experience to date at the University of 
Pittsburgh Transplantation Institute. Finally we shall 
recount recent scientific advances likely to improve 
patient survival in the future. 
MICROVILLUS INCLUSION DISEASE AND 
INTESTINAL PSEUDOOBSTRUCTION 
In 1978, Davidson et al described five Canadian 
infants with a specific form of intractable diarrhea (1). 
Four of the five had a positive family history of this 
disorder. and all five had specific histologic abnormal-
ities. Light microscopy of their small intestines re-
vealed villous atrophy but no crypt hyperplasia. Elec-
tron microscopy revealed cytoplasmic vesicles near 
the apical surface of enterocytes. The vesicles pos-
sessed microvilli and secretory granules. Four of the 
first five cases died in early infancy. A subsequent 
detailed account (2) of 23 cases surveyed from around 
the world indicated that the disorder had been seen in 
patients of Caucasian. Asian and Arab lineage; there 
was a 2:1 female predominance. Most patients pre-
sented with diarrhea in the first week of life. but 
rarely it was not recognized until 40-60 days of life. 
Diarrhea was profound. with most patients losing 
200-500 cc of stool per kilogram of body weight per 
day. Malabsorption of all nutrients was evident. No 
pharmacologic intervention was especially effective. 
but parenteral somatostatin could reduce stool output 
by half. Eighty percent of the children died during 
infancv with the rest bound inextricablv to TPN. It is 
notabie that loss of venous access for o~ly a few hours 
could lead to death from dehydration in these pa-
tients. 
Chronic intestinal pseudoobstruction is character-
ized by the signs and symptoms of intestinal obstruc-
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tion without anatomic obstruction (3). Cases that are 
not secondary to hypothyroidism. scleroderma, amy-
loidosis, gastroschisis, Hirschsprung's disease, or 
other disorders are deemed idiopathic. The two ma-
jor categories of idiopathic pseudo obstruction are the 
neuropathic and the myopathic forms. With either of 
the two types, symptoms begin at birth in 50% of 
patients and by age one year in 75%. Almost half the 
patients, regardless of type, have small bowel malro-
tation. Bilious vomiting, abdominal distension, and 
obstipation are almost universally present, but para-
doxically, some patients develop secretory diarrhea. 
The severity of symptoms will wax and wane during 
the first several years of illness. Patients with the 
neuropathic form are more likely to have severe, 
incapacitating abdominal pain, and those with the 
myopathic form are at risk for spontaneous bowel 
perforation. Megacystis and megaureter are frequent 
accompaniments. The entire bowel may be involved 
or there may be selective involvement of the colon. In 
some cases the disorders seem to be acquired and 
may progress from isolated colonic involvement to 
total involvement of the alimentary canal. Manomet-
ric changes range from absent or decreased motility 
in the myopathic form to high-amplitude, nonpropo-
gated clusters, retrograde propogation, or failure to 
produce a fed pattern in the neuropathic form. Some 
patients derive transient benefit from pharmacologic 
therapy with prokinetic drugs or somatostatin, and 
others can be fed by slow continuous enteral feeding 
through a jejunostomy or gastrostomy. The subset of 
these patients incapable of tolerating adequate en-
teral calories because of visceral pain, vomiting, or 
malabsorption is faced with the prospect of receiving 
TPN. When TPN complications become life-threat-
ening, multivisceral transplantation is necessary. 
SHORTBO~LSYNDROME 
Short bowel syndrome accounts for the majority of 
pediatric referrals for small intestinal transplantation 
(Table 1). The most common disorders requiring 
massive intestinal resection include necrotizing en-
terocolitis. midgut volvulus. gastroschisis. and con-
genital small bowel atresias. 
Following resection. the length of the remaining 
bowel does not correlate perfectly with prognosis. 
One reason is that bowel length can not be measured 
very precisely. Measured length depends upon the 
extent of contraction or relaxation at any point in 
time. For example. 350 cm of bowel measured ill vim 
may expand to 600 em in a postmortem examination 
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TABLE 1. CAUSES OF INTESTINAL FAILURE IN 
CHILDREN 
Volvulus 
Gastroschisis 
Necrotizing enterocolitis 
Intestinal atresia 
Pseudoobstruction 
Microvillus inclusion disease 
Intestinal polyposis 
Hirschsprung's disease 
Total 
10 
8 
6 
7 
4 
3 
1 
1 
41 
(4). Additionally, inflamed bowel undergoes shorten-
ing postoperatively. 
Other factors influencing the prognosis of short 
bowel syndrome include the gestational age of a new-
born at the time of small bowel resection, the post-
natal age of the patient at the time of resection, the 
remaining length of small bowel after resection, the 
site of remaining small bowel, the presence or ab-
sence of an ileocecal valve, the remaining length of 
colon after resection, and the amount of damage 
incurred by the remaining gastrointestinal tract at the 
time of initial insult (5). 
Duodenal resection leads to disproportionate mal-
absorption of minerals and folic acid. Jejunal resec-
tion disproportionately impairs protein and carbohy-
drate absorption (6), which can be partially overcome 
if ileal length is adequate. However, jejunectomy also 
results in decreased production of cholecystokinin 
and secretin, which in tum leads to gallbladder stasis 
and decreased exocrine pancreatic secretion. Inade-
quate jejunal production of gastric inhibitory 
polypeptide (GIP) and vasoactive intestinal polypep-
tide (VIP) combined with reduced gastrin catabolism 
result in increased serum gastrin and gastric hyperse-
cretion (7). 
Massive ileal resection not only decreases overall 
intestinal absorptive surface area but also disrupts the 
enterohepatic circulation of bile salts. leading to ei-
ther a depleted bile salt pool and steatorrhea, or bile 
salt-mediated diarrhea (8). Absorption of vitamin BI2 
may also be inadequate following extensive resection 
of the terminal ileum (9). Resection of the ileocecal 
valve shortens intestinal transit time and permits co-
lonic contents to regurgitate into the small bowel. 
resulting in small bowel bacterial overgrowth syn-
drome (to). 
Disaccharide intolerance frequently accompanies 
short bowel syndrome and other types of intestinal 
failure. Malabsorbed carbohydrates are fermented by 
colonic flora to produce short-chain fatty acids such 
as acetate. butyrate. and propionate (11. 12). 
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Among patients with steatorrhea. luminal ionized 
calcium is saponified by fatty acids. resulting in exces-
sive free oxalate presented to the colon. Increased 
colonic absorption of free oxalate leads to hyperox-
alurea. placing patients at risk for oxalate urolithiasis 
(13 ). 
INTESTINAL ADAPTATION 
The capacity for intestinal adaptation following 
massive small bowel resection is governed by a variety 
of factors. In general, children seem to be more 
capable of adapting than are adults (14-19). Success-
ful adaptation is also facilitated by the presence of the 
ileocecal valve. In his classic treatise, Wilmore (14) 
showed that sUlvival was possible among infants left 
with 15 cm of jejunum and ileocecal valve. Forty 
centimeters of jejunum were necessary for survival if 
the ileocecal valve had been sacrificed. More recent 
publications (15-18) have described survival among 
children with as little as 10 cm of remaining bowel, 
but an intact ileocecal valve remains an important 
determinant of survival. 
Adaptation results in increased villous height, in-
testinal length, and intestinal diameter. Individual 
cellular absorptive capacity does not improve, but the 
number of cells per unit of surface area increases 
(19). In unfed animals, disuse villus atrophy occurs 
within three days of a resection, but early institution 
of enteral feeding promotes recovery and enhances 
intestinal adaptation. 
Enterocytes, which have the greatest energy re-
quirements of all types, utilize glutamine in prefer-
ence to glucose (20). This observation has led inves-
tigators to study the effects of parenteral or enteral 
glutamine supplementation upon the small bowel mu-
cosa when the gastrointestinal tract is stressed and the 
muscle glutamine pool is likely to be depleted. Wil-
more's group has shown that TPN-induced mucosal 
atrophy in rats can be partially corrected by glutamine 
enrichment of parenteral aminoacids (21). An isoni-
trogenous quantity of glycine will have comparable 
effects when delivered at 1 g/100 ml but not at 2 g/100 
ml. In an animal model of short bowel syndrome. this 
same group showed that altering the dietary compo-
sitions of an dimental diet such that glutamine com-
prised 250 of the total amino acids resulted in sig-
nificantly improved adaptation (22). Human studies 
hv this group suggested that substitution of other 
amino acids with an isonitrogenous yuantity of oral 
glutamine combined with pharmacologic parenteral 
Lioses of growth hormone could improve caloric ab-
sorption by about 20% and reduce stool output by 
about 25% in the limited number of adults with short 
bowel syndrome who were tested (23). Animal studies 
by Vanderhoof and colleagues cast some doubt upon 
the salutary effect of enteral glutamine insofar as 
substitution of glycine or glucose for glutamine in 
isocaloric quantities led to comparable or better ad-
aptation following 80% bowel resection (24, 25). 
Problematic patients are those whose small bowel 
never adapts, those who develop cholestasis and sub-
sequent end-stage liver disease associated with TPN, 
those with multiple technical line complications, 
those who develop severe infectious and metabolic 
complications of TPN, and those who experience an 
unsatisfactory quality of life secondary to their under-
lying intestinal disorder. 
TPN-ASSOCIATED LIVER DISEASE 
A variety of liver disorders may beset patients 
bound to TPN. Fatty liver and hepatic fibrosis are 
common in adults and older children receiving TPN. 
Those changes are linked to the delivery of excessive 
carbohydrate calories (26). In contrast, cholestasis is 
commonly observed among infants and younger chil-
dren (27, 28). Both exogenous (TPN-related) factors 
and individual host factors place patients at risk for 
cholestasis. The TPN-related factors (28) most often 
implicated include provision of excessive protein; pro-
vision of excessive glycine, alanine, and tryptophan; 
provision of flavinoids, which are photooxidized to 
toxic products; or provision of insufficient antioxi-
dants such as selenium or tocopherol. Finally, relative 
taurine deficiency may be instrumental in the chole-
static process. 
It is well recognized that cholestasis begins earlier 
and is more severe among infants receiving more than 
2 g proteinikg body weight/day by the parenteral 
route as compared with counterparts receiving ::'::2 
g/kgJday (29). Furthermore, glycine and alanine will 
produce a significant cholestatic effect when perfused 
into isolated. perfused rat liver (30). The sulfated 
amino acid tryptophan is also cholestatic, but its cho-
Iestatic effect is enhanced by photooxidation to tryp-
tophan sulfoxide (31). Riboflavin seems not only to 
facilitate the photooxidation of tryptophan but also 
hecome photooxidizeLi to a potential hepatotoxin it-
self (32). Taurine is a provisionally essential amino 
acid in premature infants. malnourisheLi patients. or 
cirrhotic patients who do not possess enough cysta-
thionine synthetase or S-adenosylmethionine syn-
thetase to permit taurine synthesis by trails sulfura-
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tion of methionine. In the case of taurine deficiency, 
mono hydroxy bile acids are preferentially conjugated 
with glycine. rendering them more hepatotoxic than 
their taurine-conjugated counterparts (33). 
Host-related factors (34) playing a role in cholesta-
sis are a reduction in bile acid pool due to prematurity 
or intestinal bile acid wasting, the development of 
biliary sludge due to prolonged fasting or insufficient 
cholecystokinin production, the loss of portal hepa-
totrophic factors in the absence of enteral feeding, 
excessive portal vein concentrations of endotoxin 
leading to reduced bile flow, or the damaging effects 
of bacterial cell wall glycoproteins upon hepatic func-
tion after bacterial translocation across the intestine. 
Liver abnormalities can be reversed if intestinal 
function permits early initiation of enteral nutrition, 
minimizing the need for TPN. Cycling of parenteral 
nutrition, protecting solution from light (32), supple-
menting with taurine (33), and judiciously employing 
oral antibiotics for selective bowel decontamination 
(35) are all accepted therapeutic strategies. More 
recently animal studies have suggested that prophy-
laxis with intravenous ursodeoxycholic acid prevents 
TPN cholestasis (36). Pilot human studies (37, 38) 
suggest that oral ursodeoxycholic acid may actually 
reverse cholestasis in TPN-bound patients. However, 
a subset of patients with irreversible bowel dysfunc-
tion may develop irreversible liver damage within 
months or years after TPN is started. Isolated ortho-
topic liver transplantation may be an unwise option 
for them because the need for TPN will persist, with 
subsequent damage to the new liver. Additionally, the 
short segment of remaining bowel may not permit 
satisfactory Roux-en-Y biliary drainage of the al-
lograft liver, and a duct-to-duct biliary anastomosis 
may be technically impossible. 
INDICATIONS FOR SMALL BOWEL 
TRANSPLANTATION 
In order to qualify for combined small bowel-liver 
transplantation, the patient must be plagued by irre-
versible intestinal failure, TPN dependency, and end-
stage liver disease (39,40). Patients without end-stage 
liver disease but with severe hepatic fibrosis or cir-
rhosis are more problematic. In this group, it may be 
difficult to judge the amount of functioning liver 
necessary to withstand the insult of portal diversion 
during small intestinal transplantation. It is also pos-
sible that a persistent need for TPN during the first 
few posttransplant weeks might lead to irreversible 
hepatic damage. Thus. all such patients are listed for 
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a combined small bowel-liver transplant: however, the 
flnal decision of allograft type will likely be made in 
the operating room after assessing for evidence of 
portal hypertension and judging the severity of cir-
rhosis at the time an organ becomes available. 
TPN-dependent patients without liver disease must 
also satisfy rigorous criteria before being considered 
active candidates for isolated intestinal transplanta-
tion. Their intestinal disease must be irreversible, and 
they must be TPN-dependent. Additionally, at least 
one of the following criteria must be met: inadequate 
venous access must imperil the ability to administer 
TPN, the risk for fatal TPN complications (such as 
recurrent sepsis) must be substantial, or the underly-
ing disease process (such as microvillus inclusion dis-
ease or diffuse juvenile polyposis) must be life-
threatening. 
SURGICAL TECHNIQUE 
The abdominal viscera are analogous to a cluster of 
grapes and each of the organs (the grapes) may be 
transplanted singly or in groups (41). Two central 
stems (the celiac axis and the superior mesenteric 
artery) supply arterial blood. These arteries can be 
anastomosed to the infrarenal or supraceliac aorta. 
Venous drainage of the small bowel-liver allograft is 
into the confluence of the recipient hepatic veins, 
whereas the isolated small bowel allograft can be 
drained into the recipient portal vein, splenic vein, or 
inferior vena cava (as a permanent mesocaval shunt). 
The donor ileocecal valve and colon can be in-
cluded in the graft to enhance water and electrolyte 
absorption. 
Figure 1 illustrates isolated small intestinal trans-
plant. Figure 2 describes small bowel transplantation 
in conjunction with a liver graft. A multivisceral graft 
is shown in Figure 3. 
POSTOPERATIVE CARE 
Induction and maintenance immunosuppression 
are achieved using the macrolide immunosuppressant 
agent, tacrolimus (30, 31), which is not only 100 times 
more potent than cyclosporine A. but is also absorbed 
quite well in the upper gastrointestinal tract in the 
absence of intraluminal bilt: acids. This agent func-
tions like cyclosporinc to inhibit T-cell production of 
interleukins 2. 3. and 4 as well as granulocyte stimu-
latory factor and interferon-a (42). I t produces some-
what less hypertension and markedly less hirsutism 
and gingival hyperplasia than does cyclosporine (43). 
SMALL INTESTINAL TRANSPLANTATION 
Fig 1. Isolated small bowel transplantation: (A) Donor operation: 
full-length vascular pedicle of the superior mesenteric artery 
(SMA) with Carrel patch and superior mesenteric vein (SMV). are 
divided more distally, they can be lengthened on the back table 
with arterial and venous grafts (insert). (B) Recipient operation. 
AnastomosIS of the full length of SMA to the aorta and the angled 
end of the SMV to the po~tal vein. In an alternative method~the 
SMV is anastomosed to the recipient SMV inferior to the pancreas 
(lower insert'. Option of SMV dramage into the inferior vena ca .... a 
IS shown In upper insert. 
The dose used is 0.1 mg;kg/day by continuous intra-
venous infusion. beginning immediately after reper-
fusion of the allograft. A whole blood level of 15-20 
ng;ml is desirable. As soon as postoperative ileus 
!)/!.!t'S({\'/' f)1\t·a.\'~s wid SClt'nn's. "01. -I~ . .\'0. 10 (()('foha i')C)71 
resolves. oral tacrolimus is started at a dose of 0.2 
mg/kg/day and overlapped with intravenous tacroli-
mus for a day or two to ensure therapeutic plasma 
levels. 
Adjuvant steroid therapy is initiated during the 
operation and customarily eliminated within a few 
weeks based on the patient's clinical condition. Pa-
tients usually receive an intraoperative parenteral bo-
lus of intravenous hydrocortisone (300-500 mg for 
children weighing less than 20 kg, 500-1000 mg for 
children weighing more than 20 kg) followed a day 
later by a methylprednisolone taper administered in-
travenously, beginning at approximately 5 mg/kglday. 
Within 5 days the dose is tapered to a baseline of 1 
mg/kglday by mouth. The baseline dose is maintained 
for the shortest possible period before being discon-
tinued. Prostaglandin El is administered as a contin-
uous infusion for five days at a dose of 0.003-0.009 
p.g/kglhr to augment immunosuppression (44). Aza-
thioprine is provided at a dose of 1-2 mg/kglday. It is 
initially given intravenously and later by mouth. Table 
2 outlines the immunosuppression regimen currently 
employed at the University of Pittsburgh. 
MONITORING OF REJECTION 
Serum liver enzyme levels are measured frequently, 
and liver biopsies are performed periodically. Liver 
allograft rejection is monitored just as it would be for 
patients who have undergone isolated liver transplan-
tation. Rejection of the gastrointestinal tract is sus-
pected anytime the patient's clinical picture deterio-
rates, stomal output increases or decreases, 
endoscopic examination becomes abnormaL or histo-
logic features of rejection appear. Endoscopic biop-
sies can be obtained by esophagogastroduodenos-
copy, stomal endoscopy, or colonoscopy. These are 
performed as frequently as twice a week initially or 
whenever the index of suspicion for rejection is high. 
Clinical findings prompting endoscopic evaluation are 
fever, ileus, increased stoma output, or gastrointesti-
nal bleeding. 
Endoscopically, early signs of rejection are edema, 
erythema, friability. and aperistalsis. Progression to 
aphthoid ulcers and ultimately, broad-based ulcers 
with overlying pseudomembrane occurs when immu-
nosuppression is inadequate (45, 46). 
Histologic characteristics (Figure 4) of intestinal 
acute cellular rejection are activated lymphocytes at-
tacking crypt epithelium and patchy epithelial apo-
ptosis (47). Severe rejection may progress to desqua-
mation and diffuse pseudomembranous enterocolitis. 
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Fig 2. (A) Small bowel-liver allograft. Note the continuity of donor portal vein. (8) Recipient 
operation. Carrel patch containing the origin of the SMA and the celiac axis is anastomosed 
to the aorta. Ideally. the venous return from residual splanchnic viscera of the recipient is 
routed by vascular anastomosis into the graft portal vein. Numerous options of graft 
reanerialization and venous drainage have been described elsewhere. 
Regeneration may occur in such instances but usually 
after long, intensive courses of immunosuppression 
(48). Of our eight pediatric patients experiencing 
severe exfoliative rejection, three underwent graft 
enterectomy, with one being subsequently success-
fully retransplanted. Yet a fourth underwent imme-
~()()2 
B 
Fig 3. ~lultivisceral allograft (AI hefore ano (8) after transplantation. SpkneClllnlV " 
performed on the hack tahk. In this case the Carrel patch with the superior mcsenteric arter. 
ano celiac axis migins has hCl.!n u"o to cap a trce gratt ot d,)I1or thoracIC aorta that has hecn 
used as a mnouit. This is (lnlv onc of thc scycraloptions that the operator should he prepared 
to exercisc. 
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T\IlLE 2. l\1\ll~()'ilPl'ln:sSt():'i RE<d\IF~ ['OR PI·D\.\ 11<1(" S\\'\I.L 
BOWEL TR.\~'iI'L"T-\TI()'i 
I. Cllrtlc()steroid 
\. Initial 
I Hvdrocortisone 
a. 300-S00 1m! IV if weight <2() h 
h. SOO-WOO I~H! IV if wc-ight >2(} kg 
~. SterOid cycle \~ith methylprednisoil;ne 
a. 5 mg;kg IV during first postoperative day 
h. Reduce hy I mg/kg/day to haseline of I mg;'kg IV hv 
postoperative day S 
B. Long-term 
l. Switch to oral methylprednisolone I mgrkg when 
tolerating oral alimentation 
2. Attempt further tapers and discontinuing within 4-6 
weeks if rejection is under control 
II. Tacrolimus 
A. Initial 
l. 0.1 mg;kg by continuous IV infusion 
2. Overlap oral with IV for I or 2 days; as levels climb. 
discontinue IV tacrolimus 
ill. Azathioprine 
I. 1-2 mg;kg;dav IV until tolerating oral alimentation. then 
switch ~to ~orai ~ 
I V, Prostaglandin E 
I. O,003-..{J.()09 /Lg/kg/hr bv continuous IV infusion for 5 
days 
diate liver-small bowel retransplantation but died 
after a disseminated adenovirus infection. 
Endoscopic and histologic changes may involve 
small bowel, stomach. and colon simultaneously or 
changes may be confined to one anatomic area (49). 
Usually the ileum is the most severely damaged re-
gion. but occasionally the jejunum is preferentially 
affected. 
We have identified "chronic intestinal rejection" in 
one adult patient but among none of our pediatric 
recipients (50). That patient. who stopped his immu-
Ilosuppression months after transplantation. devel-
oped a "wasting disorder" characterized by steator-
rhea. Small bowel endoscopy was normal. but patchy 
villous atrophy was present histologically. More im-
pressive than mucosal abnormalities were submucosal 
changes. including smooth muscle hypertrophy ami 
vascular obliteration. which would have been missed 
with mucosal biopsy. Superior mt:st:ntt:ric arteriogra-
phy revealed segmental narrowing of jejunal and ileal 
arteries. Either lull-thickness biopsy or angiography is 
thus re4uirl:d to establish the diagnosis of chronic 
rejection. 
CONTROL OF REJECTIO,\ 
This is aehievl:d by modulating immunosupprl:ssive 
.lgents to aehil:\'l: optimal Icyds (39. -HI). The tacroli-
Il1US dllSl: mav he incrclsed. a stl:roid bolus mav be 
given. or a steroid "recycle" may be initiated. OKT3 
may be used in severe or refractory acute cellular 
rejection. 
INFECTION SURVEILLANCE AND TREATMENT 
Infection control plays a key role in success of small 
bowel transplantation (39. 40). The mucosal barriers 
of native bowel permit very little translocation of 
bacteria or yeast into mesenteric lymphatics, but once 
there, gut organisms are transported by macrophages 
to regional mesenteric lymph nodes for immunologic 
recognition and surveillance. In the transplanted 
bowel, this orderly process may be impaired by im-
munosuppression, luminal microbial overgrowth, dys-
function of gut-associated lymphocytes during graft 
repopulation by recipient cells, and acute cellular 
rejection. Increased numbers of gram-negative aer-
obes such as E. coli, Klebsiella. and Pseudomonas can 
translocate from gut lumen directly into the portal 
circulation, leading to life-threatening sepsis. Hence 
judicious postoperative use of antimicrobial agents is 
imperative. 
Intravenous, broad-spectrum antibiotics are given 
for five days postoperatively and for 24 hr following 
endoscopic procedures. Oral. nonabsorbable antibi-
otics (including amphotericin and an aminoglycoside) 
are given for several weeks routinely and subse-
quently whenever stomal gram-negative microbial 
counts exceed lOX colony forming units per milliliter 
in an effort to selectively decontaminate the bowel. 
The purpose of selective decontamination is to re-
duce numbers of intraluminal, gram-negative aer-
l)bes. thereby permitting anaerobes (which are less 
likely to induce septicemia) to proliferate (51). 
Pneumocystis. cytomegalovirus. and herpes pro-
phylaxis arc accomplished with prophylactic tri-
methoprim-sulfa. ganciclovir. and acyclovir. respec-
tively. 
POSTOPERATIVE NUTRITIONAL SUPPORT 
As soon as postoperative ileus resolves, jejunos-
tomy feeding is bt:gun as a continuous. low-volume 
infusion of age-appropriate sl:mieleml:ntal formulas. 
During the first six years of the program. patients 
were generally started on formulas containing ther-
mallyor enzymatically hydrolyzed cow's milk protein. 
More recent transplant recipients have initially rc-
ceived To\crex. which contains glutamine. Because 
mesenteric lymphatics compromised at the time of 
transplantation may rL'quirc several wl:eks to recana-
lize. this luw-fat formula is usually \\dl tolerated. 
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Fig 4. Focus of activated lymphocytes within lamina propria (A) in a patient experiencing acute cellular rejection of the small intestine 
(hematoxylin and eosin. 40x). High power view of acute cellular rejection (B) showing apoptotic crypt epithelial cells (arrows) adjacent 
to normal epithelial cells (hematoxylin and eosin. 250x). 
After two or three weeks. fat is provided as a mixture 
of long-chain fats and medium-chain triglycerides 
that can be absorbed directly into the portal circula-
tion. However. essential fatty acids are provided in-
travenously and (to some extent) enterally to prevent 
deficiency. The carbohydrate given is a mixture of 
oligosaccharides and glucose. If elemental formula is 
tolerated for sevt:ral weeks. nutritionally defined for-
mulas such as Pediasure or Peptamin Jr are delivered 
nrally or by continuous nocturnal intragastric infu-
sion. Patients are also fed general diets ad libifllm. 
Parenteral nutrition. which is begun during the 
early postoperative period. is continued until such 
time as the allograft absorptive capacity is adequate 
to sustain life. Notably. we have not seen significant 
TPN-associated hepatic dysfunction in any patients 
who arc also receiving enteral nutrition. 
2004 
ASSESSMENT OF ALLOGRAFT ABSORPTIVE 
FUNCTION 
Hematologic and biochemical blood tests are per-
formed to assess the state of hydration and renal 
function. Stomal output, urine output. and daily body 
weights are meticulously recorded and serve to guide 
fluid and electrolyte balance. 
Stomal absorption testing is performed periodically 
to assess absorption of nutrients. Seventy-two-hour 
fecal fat balance is conducted as soon as the diet 
contains substantial quantities of long-chain fats. Fat-
soluble vitamin levels arc measured several weeks 
after weaning from parenteral nutrition. A stable or a 
rising serum albumin level and improved anthropo-
metric measurements and growth velocity indicate 
satisfactory absorption of proteins. Daily measure-
ment of reducing sugars in stomal emuent as well as 
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periodic measurement of D-xylose ahsorption are 
means of assessing carhohydrate and monosaccharide 
absorption. Serum calcium. phosphorus. magnesium. 
iron. trace element levels. and tacrolimus levels while 
rhe patient is off parenteral supplements are also 
:llarkers of graft function. 
OUTCOME 
Between May 1990 and June 1995.44 small bowel 
grafts were transplanted into 41 pediatric patients 
aged 6 months to 18 years at the University of Pitts-
burgh Medical Center. Table 1 enumerates the causes 
of intestinal failure in these patients. Organs trans-
planted were an isolated small bowel graft in 10 and 
small bowel with liver in 27. Multivisceral transplants 
including stomach and pancreas were performed in 
six. and one patient received a multivisceral trans-
plant without the liver. Between January and June 
1995. five of the transplant recipients received simul-
taneous bone marrow infusions to enhance the estab-
lishment of chimerism. Twenty-four children are still 
alive from two months to five years postoperatively. 
Four of the five receiving bone marrow have survived 
for three to six months. As of June 1995, 21 of the 24 
living children were off TPN and exclusively on en-
teral feeding. 
The pediatric deaths were due to sepsis in four 
patients. respiratory syncitial virus (RSY) pneumonia 
in two. GYHD in one. and posttransplant Iymphopro-
liferative disease (PTLD) in three. cerebral infarction 
in one. rejection in four. iatrogenic salt toxicity in one. 
and respiratory failure after line insertion in one. 
OBSTACLES TO SUCCESSFUL INTESTINAL 
TRANSPLANTATION 
The successful intestinal transplant requires careful 
attention to detail. The transplant team should not 
only possess the technical expertise to perform the 
surgery hut also the willingness to provide meticulous 
rostoperative care to the transplant recipient. Any 
successful management strategy must include recog-
nition and anticiration of potential ohstacles to suc-
cess. ;\ t"t:w of those obstacles will be discussed indi-
\iduallv. 
Fluid and Electrolyte Imbalance 
Patients receiving a small intestinal transplant un-
dergo ileostomv to permit easy endoscopic monitor-
ing tor rejection. They arc thus subject to high output 
Ileostomy drain;lge until sllch time as absorption ma-
lures. fluids ;ll1d electrolytes arc Initially provided 
intravenously but as intestinal function matures. they 
may be delivered enterally via a feeding jejunostomy. 
Not only is the sodium requirement quite substantial. 
but calcium and magnesium levels must be monitored 
closely and daily supplements of each must be pro-
vided for several weeks. 
Rejection 
Almost all patients experience rejection at least 
once during the postoperative period. but the spec-
trum of severity is quite broad. Rejection may be 
severe and intractable, beginning with the first post-
operative week and progressing to death or enterec-
tomy despite an intensive course of immunosuppres-
sion. Conversely, some patients experience only mild, 
episodic asymptomatic histologic rejection that, if left 
untreated. may become clinically apparent. 
Therefore. close endoscopic and histologic moni-
toring is imperative. It has been our policy to perform 
surveillance ileoscopy twice weekly or at the first sign 
of clinical deterioration. Notably, gram-negative sep-
sis often accompanies rejection. Thus. signs of sepsis 
should not lull the clinician into excluding rejection as 
a cause of symptoms (52). Rejection is patchy in 
distribution. usually involving the ileum, but occasion-
ally preferentially involving the proximal small intes-
tine (49). 
After several postoperative months. patients are 
usually quite stable and the risk for rejection declines. 
However. viral enteritis occurring months or years 
after transplantation may result in malabsorption of 
tacrolimus resulting in late-onset rejection. Hence, a 
sense of vigilance must be maintained indefinitely. 
Viral Infections 
Invasive cytomegalovirus (CMY) infections con-
tinue to plague pediatric small bowel transplant re-
cipients. As with liver transplantation. infections ap-
pear most frequently in CMY-negative recipients who 
have received a CMY-positive grafts. Infections are 
characterized by hepatitis and by hemorrhagic en-
terocolitis. Fortunately. the lise of prophylactic gan-
ciclovir during the first two postoperative weeks 
seems to he associated with a reduced risk for infec-
tion (53). Furthermore. active infection can be suc-
cessfully treated without appreciably reducing immu-
nosuppression by using a several week collrse of 
parenteral gancyclovir (54). 
In contrast. [pstein-13arr virlls ([BY) infections 
.Ire more difncult to treat. Like recipients of solid 
llrgans. intestinal transplant recipients ;Ire prone to 
develop [BY -;I~S()Claled posttransplant Iymphopro-
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[iferative disease (PTLD). which straddles the border 
between infection and neoplasia (55). These lym-
phoid tumors are characterized bv destructive Ivm-
phoid infiltrates, gross tumors. c1o~al proliferatio~ of 
lymphocytes. and (frequently) progression to neopla-
sia. No effective antiviral agent exists for PTLD. 
PTLD may appear among immunosuppressed organ 
recipients either as a primary infection or reactivation 
of remotely acquired disease. Children. who are more 
likely to develop primary EBV infections, seem to be 
at greater risk than are adults for PTLD. The risk is 
also enhanced among children who have had rejec-
tion severe enough to require high doses of tacroli-
mus, multiple steroid recycles, and OKT3. Splenec-
tomy appears to be an independent risk factor (56). 
Antiviral strategies such as treatment with acyclovir. 
ganciclovir. and interferon-a have been disappoint-
ingly unsuccessful (42). Like liver transplant recipi-
ents with PTLD, small bowel transplant recipients 
with PTLD should undergo reduction in immunosup-
pressive doses. However, unlike liver transplant re-
cipients. they can not rely upon tumor anergy to 
protect against rejection if immunosuppression is dis-
continued. Therapy of concommitant PTLD and re-
jection has been characterized as "a therapeutic tight-
rope" whereby aggressive treatment of rejection leads 
to progression of PTLD and aggressive reduction in 
immunosuppression results in severe rejection. 
Graft-versus-Host Disease (GVHD) 
The use of tacrolimus. steroids. and azathioprine 
has rendered groundless the concern that GVHD 
would be a major clinical problem among small bowel 
transplant recipients. In the Pittsburgh series. GVHD 
was observed only in rare and unusual circumstances. 
One patient with jejunal atresia and common variable 
immune deficiency developed GVHD soon after 
transplantation. Another, who experienced severe re-
jection. underwent removal of the allograft. Transient 
GVHD induced by residual dendriti~ (antigen pre-
senting) cells developed only after removal of the 
allograft and cessation of immunosuppression. 
Intestinal Dysmotility 
A small subset of intestinal transplant recIpIents 
have undergone formal manometric testing (57). In 
those patients examined during fasting periods. antral 
waves were of reduced amplitude and frequency. Mi-
grating myoelectric complexes (MMCs) originated in 
the stomachs onlv when stomach and sm"all bowel 
were transplanted in continuitv. When isolated small 
howel transplant was performe·d. MMCs originated in 
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the allograft and could be retrograde. ante grade. or 
simultaneous. No patient had a normal fed pattern. 
Denervation of the bowel and use of tacrolimus. 
which may itself effect motility. were undoubtedly 
contributory factors. Regardless of these abnormali-
ties, all patients tolerated oral and enteral nutrition. 
FUTURE TRENDS IN TRANSPLANTATION 
Even though transplantation has progressed greatly 
since its inception in 1959, the mortality rate remains 
quite high and the degree of immunosuppression 
required remains worrisome. Until newer, more re-
fined immunosuppression becomes available, an ef-
fective approach may be the enhancement of systemic 
chimerism (58). 
Chimerism is known to occur following intestinal 
transplantation. Epithelium of the allograft is donor-
derived, but Peyer's patches become populated by 
recipient lymphocytes. Additionally, donor dendritic 
cells are commonly engrafted into distant organs of 
the recipient. The model best explaining this phenom-
enon is the two-way mixed lymphocyte reaction, 
which can also occur after bone marrow transplanta-
tion if recipient marrow is not cytoablated. It has been 
shown that immunologic tolerance can be conferred 
after solid organ transplantation if chimeric environ-
ment is enhanced by simultaneous bone marrow 
transplantation (58). This rationale has governed our 
performance of simultaneous bone marrow infusion 
and intestinal transplantation in five of our most 
recent six intestinal transplants. It is too early to judge 
the beneficial effect of this strategy, but the early 
()utcome in our small series of patients receiving bone 
marrow-intestinal transplants has been quite favor-
able. 
The need for immunosuppression in the first post-
operative weeks has not been excessive, and it is 
anticipated that the need for long-term immunosup-
pression will be reduced after a period of time. While 
the techniques for producing donor-recipient immu-
nologic balance are far from perfect. we remain op-
timistic that enhancement of chimerism will success-
fully minimize the need for pharmacologic 
immunosuppression as well as its numerous undesir-
able side e1l'ccts. 
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